Filing Analysis
📄 Other SEC Filing
Filed Jun 05, 2026
⚪ LOW
PMV Pharmaceuticals reported the results of its 2026 Annual Meeting of Stockholders held on June 4, 2026. The stockholders elected two Class III Directors, approved executive compensation on a non-binding advisory basis, and ratified Ernst & Young LLP as the independent auditor for fiscal year 2026.
📋 Key Facts
- Election of David H. Mack, Ph.D. and Laurie Stelzer as Class III Directors to serve until the 2029 annual meeting.
- Executive compensation was approved on a non-binding advisory basis with 15,015,578 votes FOR and 6,468,718 votes AGAINST.
- Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 28,379,108 votes FOR.
📢 Regulation FD Disclosure
Filed May 12, 2026
⚪ LOW
PMV Pharmaceuticals, Inc. reported its financial results for the first quarter ended March 31, 2026. The filing serves as a formal disclosure of the company's quarterly performance via an attached press release.
📋 Key Facts
- The report was filed on May 12, 2026, covering the fiscal quarter ended March 31, 2026.
- The disclosure was made under Item 2.02 (Results of Operations and Financial Condition).
- A press release detailing the financial results was furnished as Exhibit 99.1.
- The information provided is furnished and not deemed 'filed' for purposes of Section 18 of the Exchange Act.
📢 Regulation FD Disclosure
Filed Mar 06, 2026
⚪ LOW
PMV Pharmaceuticals, Inc. announced its financial results for the fiscal year ended December 31, 2025, via a press release on March 6, 2026.
📋 Key Facts
- The company reported financial results for the full year ended December 31, 2025.
- The announcement was made on March 6, 2026.
- The financial information was furnished under Item 2.02 and is not deemed 'filed' for purposes of Section 18 of the Exchange Act.
- Michael Carulli, CFO, signed the report.
Disclaimer: This analysis is generated by AI and is for informational purposes only.
It does not constitute financial advice, investment recommendations, or an offer to buy or sell securities.
Always review the original SEC filings and consult a financial advisor before making investment decisions.